Literature DB >> 8430365

Tumor necrosis factor-alpha inhibits in vivo collagen synthesis.

M C Regan1, S J Kirk, M Hurson, M Sodeyama, H L Wasserkrug, A Barbul.   

Abstract

In this study we sought to determine the in vivo role of tumor necrosis factor-alpha (TNF-alpha) at the wound-healing site. In vivo abrogation of endogenous TNF-alpha activity in experimental wounds by administration of anti-murine TNF-alpha rabbit serum resulted in a significant 77.5% increase in wound collagen deposition, as assessed by wound sponge granuloma hydroxyproline content. Administration of pharmacologic doses of recombinant murine TNF-alpha into subcutaneously inserted polyvinyl alcohol sponges resulted in an increase in collagen deposition (1594 +/- 117 vs 1014 +/- 49 and 1588 +/- 135 vs 1014 +/- 49 micrograms/100 mg sponge, for TNF-alpha in situ administration at a dose of 0.05 and 0.5 micrograms, respectively). This effect could be abolished by the simultaneous systemic treatment of the animals with the antiinflammatory drug indomethacin. The data suggest that the enhanced collagen deposition after TNF-alpha administration is a consequence of a nonspecific inflammatory activity that indirectly promotes collagen synthesis. The data also support the hypothesis that endogenous wound TNF-alpha down-regulates collagen synthesis during normal wound healing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430365

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  Scar remodeling after strabismus surgery.

Authors:  I H Ludwig
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 2.  Radiotherapy and wound healing.

Authors:  Emma-Louise Dormand; Paul E Banwell; Timothy E E Goodacre
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

3.  The effect of oral sodium taurocholate on endotoxemia and intestinal anastomotic wound healing in rats with obstructive jaundice.

Authors:  M Sayan; A Alponat; N Yavuz; E Altinkaya; S Göksel; M Sariyar
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

4.  Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing.

Authors:  Rongkun Liu; Harbinder S Bal; Tesfahun Desta; Yugal Behl; Dana T Graves
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

5.  Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.

Authors:  Markus Streit; Zsuzsanna Beleznay; Lasse R Braathen
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

6.  Transforming Growth Factor-β1 (TGF-β1) Driven Epithelial to Mesenchymal Transition (EMT) is Accentuated by Tumour Necrosis Factor α (TNFα) via Crosstalk Between the SMAD and NF-κB Pathways.

Authors:  Lee A Borthwick; Aaron Gardner; Anthony De Soyza; Derek A Mann; Andrew J Fisher
Journal:  Cancer Microenviron       Date:  2011-07-27

7.  Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1).

Authors:  M F Siqueira; J Li; L Chehab; T Desta; T Chino; N Krothpali; Y Behl; M Alikhani; J Yang; C Braasch; D T Graves
Journal:  Diabetologia       Date:  2009-11-10       Impact factor: 10.122

8.  Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL-6 in experimental silica-induced rat peritonitis.

Authors:  H G Lee; I Choi; K H Pyun; K W Park
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Tumor necrosis factor-alpha inhibits collagen alpha1(I) gene expression and wound healing in a murine model of cachexia.

Authors:  M Buck; K Houglum; M Chojkier
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing.

Authors:  David T Efron; Daniel Most; Han Ping Shi; Udaya S Tantry; Adrian Barbul
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.